Global Female Contraceptive Market 2024-2028
The female contraceptive market is forecasted to grow by USD 4571.5 mn during 2023-2028, accelerating at a CAGR of 4.6% during the forecast period. The report on the female contraceptive market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing adoption of innovative marketing strategies, evolving consumer perspective, and availability of different methods of contraception.
Technavio's female contraceptive market is segmented as below:
ByDistribution Channel
ByProduct
- Female contraceptive devices
- Female contraceptive drugs
ByGeography
- North America
- Europe
- APAC
- South America
- Middle East and Africa
This study identifies the increasing popularity of female condoms as one of the prime reasons driving the female contraceptive market growth during the next few years. Also, technological advances in iuss and high growth of e-commerce platforms will lead to sizable demand in the market.
The report on the female contraceptive market covers the following areas:
- Female contraceptive market sizing
- Female contraceptive market forecast
- Female contraceptive market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female contraceptive market vendors that include AbbVie Inc., Afaxys Pharma LLC, Agile Therapeutics Inc., Amgen Inc., Ansell Ltd., Bayer AG, The Cooper Companies Inc., Cupid Ltd., Exeltis USA Inc., Johnson and Johnson Services Inc., Mayer Laboratories Inc., Medisafe Distribution Inc., Merck and Co. Inc., Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Veru Inc., and Viatris Inc.. Also, the female contraceptive market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.